Table 2.
ER stress is effective therapeutic target for ocular diseases
Disease | Agent | Facilitate ER stress (+)/inhibit ER stress (−) | Target | Pathway | Function in ocular diseases | Used in other fields | Reference |
---|---|---|---|---|---|---|---|
Glaucoma | 4-PBA | − | Myocilin, MMP2, and MMP9 | The whole ER stress pathway | Facilitation of myocilin outflow and degradation in TM | Heart, lung, and kidney injury | 152,153 |
Glaucoma | 4-Br-BnIm | − | GRP94 | ER stress chaperone | Inhibition of GRP94 lower the levels of mutant myocilin and save RGCs | Null | 149 |
Glaucoma | Astragaloside-IV | − | MMP3 and MMP9 | The whole ER stress pathway | Rescue TGF-β2 induced ocular hypertension by relieving RM damage | In renal and cardiac diseases | 153 |
Glaucoma | shp2 | + | PERK | PERK pathway BDNK/TrkB pathway | Knock down of Shp2 relieve ER stress | Cancer for immunotherapy, human development disorders, and aggravating psoriasis | 122,472–474 |
Glaucoma | CRISPR-Cas9 | − | Myocilin/HRH1/CHOP/ATF4 | The whole ER stress pathway | Remove MYOC mutation/alleviation of Ca2+ release/knockout UPR molecules to protect TM cells and RGCs | Null | 77,108,175 |
Glaucoma | TMAO | − | Unfolded myocilin | ER chaperone | Facilitate myocilin outflow | In urethral cycle disorders for clinical use | 151 |
Glaucoma | LDN-0060609 | − | PERK | PERK-ATF4-CHOP | Relieve ER stress and protect TM cells | In Alzheimer’s disease | 150 |
Glaucoma | siRNA | − | Mutant MYOC | The whole ER stress pathway | Repopulation of TM cells, prevention of RGCs loss, and recovery of IOP | – | 75 |
Glaucoma | siRNA | − | PKR | The PERK/ eIF2α/ATF4/CHOP pathway | Relieve ER stress and protect RGCs | – | 176 |
Glaucoma | Imidazolo-oxindole derivative | − | PKR | The PERK/ eIF2α/ATF4/CHOP pathway | Relieve ER stress and protect RGCs | – | 176 |
Glaucoma | Human trabecular meshwork stem cells | − | TM tissue | The whole ER stress pathway | Relieve of ER stress, replication of endogenous TM cells, and the restoration of the ECM structure | – | 161,162 |
Glaucoma | Induced pluripotent stem cells | − | TM tissue | The whole ER stress pathway | Relieve of ER stress and supplement of TM cells | Not used in clinic | 163 |
Glaucoma | Mesenchymal stem cells | − | TM tissue | The whole ER stress pathway | Relieve of ER stress and supplement of TM cells and protection of RGCs | Not used in clinic | 164 |
Glaucoma | Exosomes derived from bone marrow mesenchymal stem cells | − | TM tissue | The whole ER stress pathway | Protection of TM cells from ER stress | Not used in clinic | |
Glaucoma | Non‐pigmented ciliary epithelium derived exosomes | − | ECM degradation and | WNT/β‐catenin pathway and nrf2 downstream and the whole ER stress pathway | Decreased ECM and ER stress in TM tissue, and alleviation of inflammation | – | 167 |
Glaucoma | Adipose-derived stem cells | − | TM tissue | The whole ER stress pathway | Protection of TM cells from ER stress | – | 166 |
Glaucoma | Combining stem cell therapy with superparamagnetic iron oxide nanoparticles | − | TM tissue | Relieve the whole ER stress pathway | Drive the homing of stem cell and preserve TM tissue | – | 165 |
Glaucoma | Amoxapine/desloratadine/maprotiline | − | RXR | PERK-ATF4-GADD34 | Relieve ER stress | In relapsing–remitting multiple sclerosis, hematoma, diabetes, and lung cancer and | 108 |
Glaucoma | Valdecoxib | − | COX2 | PERK/ATF4/CHOP pathway | Reduce RGC apoptosis | In the treatment of osteoarthritis (OA) and arthritis | 177 |
Glaucoma | KUSs | − | ATPase | Autophagy | Protection of RGCs, amacrine cells, and photoreceptors | Ischemic neuropathy | 170 |
Glaucoma | p58IPK overexpressed by AAV | − | Neurotrophin | ER protein chaperon | Elevation of RGCs survival rate through refolding protein and inhibition of ER stress | – | 115 |
Glaucoma | Resveratrol | − | RXRs and HDAC1 | The whole ER stress pathway | Reduce ER stress-induced RGC apoptosis | – | 178 |
Glaucoma | Tubacin | − | HDAC6 | The whole ER stress pathway | Reduce oxidative stress and ER stress to protect RGCs | In the treatment of bipolar disorder and epilepsy | 134 |
Glaucoma | Valproate | − | HDAC | Bip and CHOP | Reduce oxidative stress and ER stress to protect RGCs | In the treatment of bipolar disorder and epilepsy | 136 |
Glaucoma | Rapamycin | − | Autophagy | mTOR pathway | Restore autophagy caused by OPTN mutation and relieve ER stress | – | 102 |
Glaucoma | Trehalose | − | Autophagy | Autophagy independent of mTOR pathway | Restore autophagy caused by OPTN mutation and relieve ER stress | – | 102 |
Glaucoma | Nanoparticles | − | ER stress and oxidative stress | ROS and the whole ER stress pathway | Inhibit ER stress and oxidative stress at the same time | – | 179 |
Glaucoma | Pentazocine | + | S1R | IRE1/XBP1 pathway | Upregulate the protective IRE1/XBP1 pathway and reduce the other two to protect RGCs | – | 113 |
Glaucoma | BDNF/MANF/rhNGF | − | Neurotrophin | The whole ER stress pathway | Relieve ER stress to protect RGCs | – | 117,120,181 |
Diabetic retinopathy (DR) | 4-PBA | − | The whole ER stress pathway | The whole ER stress pathway | Inhibit ER stress and protect retinal neuron | Heart, lung, and kidney injury | 152,153,187 |
DR | TUDCA | − | TGR5 | The whole ER stress pathway | Alleviate ER stress by inhibiting Grp78 translocation and reduce VEGF that protect inner BRB | – | 249 |
DR | Nobiletin | − | GADPH translocation | The whole ER stress pathway | Protect Muller glia and recover VEGF/PEDF, which protect iBRB | – | 207 |
DR | Ghrelin | − | GHSR-1a | PERK pathway | Inhibit ER stress in endothelial cells to protect inner BRB | – | 250 |
DR | Astragalus polysaccharide | − | miR-204 | miR-204/SIRT1 axis | Alleviate inflammation and reduce the apoptosis of RPE cells | In tumor treatment | 189,244,245 |
DR | Lactucaxanthin | − | ER stress, oxidative stress and inflammation | The whole ER stress pathway | Decrease vascular leakage due to rescue the destructed tight junction between RPE cells | For antioxidants, antidiabetic substance, and anticancer drugs | 208,233,246–248 |
DR | CRISPR-Cas9 technology | − | IRE1α | IRE1α/XBP1STING pathway | Protection of endothelial cells to protect iBRB | – | 213 |
DR | siRNA | − | TCF7L2 | ATF6 pathway | Protect vascular endothelial cells and iBRB | – | 217 |
DR | P58IPK | − | neurotrophin | PERK/eIF2α pathway | Protect vascular endothelial cells by inhibiting VEGF production | – | 251 |
DR | Liraglutide | − | Trx-ASK1 | Trx-ASK1complex/ER stress | Protect RGCs by inhibiting ER stress | In T1DM, T2DM, and obesity | 475,476 |
DR | Sulforaphane | − | AMPK | Inhibit ER stress by AMPK pathway | Protect retinal cells including photoreceptors by reducing inflammation, oxidative stress, and ER stress | In age-related diseases and neuroinflammation diseases | 254 |
DR | Melatonin | − | PERK pathway and Bip | PERK pathway | Prevent RGCs death via inhibiting ER stress | In the control of the circadian rhythm, immune enhancement, and antioxidant, anti-aging, and antitumor effects | 256 |
DR | Stem cell therapy | − | Adipose-derived mesenchymal stem cells | Combining the neuroprotective effect with melatonin | Neuro protection | – | 256 |
DR | Chrysin | − | UPR and AGE-RAGE | Reduction of UPR and activation of AGE-RAGE | Save the BRB by rescuing RPE and reduction of VEGF | In degenerative disorders and provides cytotoxic and anti-inflammatory functions | 194 |
DR | Penicillamine | − | Elevated copper | The whole ER stress pathway | Protect BRB by saving RPE via alleviating ER stress and MFN2 | – | 186 |
DR | Neurotrophin-4 | − | Neurotrophin | The whole ER stress pathway | Protect RGCs via inhibiting ER stress | – | 241 |
DR | NT4-polyamidoamine (PAMAM) electrostatic complex | − | Neurotrophin packed in nanoparticles | The whole ER stress pathway | Protect RGCs via inhibiting ER stress | – | 252 |
Age-related macular degeneration (AMD) | Grape polyphenols | − | ER stress and inflammation | The whole ER stress pathway | Prevent neovascularization and protect RPE | – | 293 |
AMD | Curcumin | − | ER stress | The whole ER stress pathway | Protect RPE from ER stress damage | – | 294 |
AMD | ISR inhibition | − | ER stress | The whole ER stress pathway | Prevent neovascularization via inhibition of ER stress, like ATF4 | – | 275 |
AMD | Paeoniflorin | − | CaMKII/AMPK | The whole ER stress pathway | Protect RPE | – | 295 |
AMD | Propofol | − | UPR pathway | The whole ER stress pathway | Protect RPE | – | 296 |
AMD | Humanin | − | UPR pathway | The whole ER stress pathway | Protect RPE | – | 297 |
AMD | Human umbilical cord mesenchymal stem cell-derived exosomes | − | miR-27b | The whole ER stress pathway | Secretion of miR-27b to inhibit fibrosis-induced ER stress | – | 299 |
AMD | Human retinal progenitor cells | − | UPR pathway | The whole ER stress pathway | Supplement with neural cells to compensate ER stress-induced cell loss | – | 300 |
AMD | Taurine | − | Calpain | Upregulate calpain to inhibit ER stress | Protect RPE | – | 298 |
RP | 4-PBA | − | UPR pathway | The whole ER stress pathway | Protect the whole retinal cell via inhibition of ER stress | Heart, lung, and kidney injury | 325,326 |
RP | TUDCA | − | UPR pathway | The whole ER stress pathway | Protect the whole retinal cell via inhibition of ER stress | Studied in many neurodegenerative diseases | 325,326 |
RP | Rapamycin | − | mTOR | PI3K/AKT/mTOR | Inhibit ER stress and the downstream inflammation in RPE and photoreceptors | Lifespan, cardiac disease/function, central nervous system, immune system, and cell senescence | 477 |
RP | PP242 | − | mTOR | PI3K/AKT/mTOR | Inhibit ER stress and the downstream inflammation in RPE and photoreceptors | In colon cancer and gastric cancer | 478,479 |
RP | AICAR | − | AMPK | CAMKKβ/AMPK/mTOR | Inhibit ER stress and restore autophagy | In heart diseases | 480 |
RP | Salubrinal | − | peIF2α | PERK-ATF4-CHOP | Reduce ER stress in RPE and photoreceptors | – | 308 |
RP | Bilberry extract | − | UPR pathway | The whole ER stress pathway | Protect RGC loss induced by ER stress | – | 312 |
RP | HSPA4L | − | PRPF31 mutant aggresomes | Protein chaperon | Transport PRPF31 mutant aggresomes to nuclear which protect RPE | Null | 481 |
RP | CRIPR/Cas9 | − | RHO mutation | UPR pathway | Knock out mutant RHO to reduce ER stress in photoreceptors | – | 328 |
RP | siRNA | − | RHO mutation | UPR pathway | Knock out mutant RHO to reduce ER stress in photoreceptors | – | 329 |
RP | Stem cell therapy | − | Stem cell differentiated into RPE cells | The whole ER stress pathway | Supplement with RPE, which prevent the retinal cell loss induced by ER stress | – | 331–333,335 |
RP | Exosomes derived from mesenchymal stem cell and RPE | − | UPR pathway | The whole ER stress pathway | Prevent the whole retina from the damage of ER stress | – | 337–339 |
RP | Optogenetics | − | Non-photosensitive retinal cells | The whole ER stress pathway | Converting non-photosensitive retinal cells to photoreceptors, which escape the ER stress damage resulted from RHO mutation | – | 342 |
ACHM | Fenretinide | + | ATF6 | ATF6 pathway | Increase the expression of ATF6 to protect cone photoreceptors | – | 353 |
ACHM | AA157 | + | ATF6 | ATF6 pathway | Increase the expression of ATF6 to protect cone photoreceptors | – | 349 |
ACHM | Rp-8-Br-cGMPS | − | cGMP | cGMP/PKG/ RyR2 | Elevate of intracellular Ca2+ and abolish the channel upregulation in CNG channel deficiency to reduce ER stress in cone cells | In vascular and muscle field | 348 |
ACHM | KT5823 | − | cGMP | cGMP/PKG/ RyR2 | Elevate of intracellular Ca2+ and abolish the channel upregulation in CNG channel deficiency to reduce ER stress in cone cells | In Marfan syndrome, thyroid cancer, and breast cancer | 348 |
RP | AAV | − | CNGB3 | The whole ER stress pathway | Protect cone photoreceptors | – | 356 |
RP | CRISPR/Cas9 | − | PDE6 | The whole ER stress pathway | Protect cone photoreceptors | – | 357 |
Cataracts | 4-PBA | − | Protein chaperon | The whole ER stress pathway | Reduce EMT via inhibition of ER stress and reduce opacity in lens | Heart, lung, and kidney injury | 377 |
Cataracts | Pentazocine | − | S1R | The whole ER stress pathway | Relieve ER stress, OS, and cell apoptosis in lens cell | – | 378 |
Cataracts | Iontophoresis | − | Delivery system | The whole ER stress | Combining it with ER-targeted drugs to reduce opacity in lens | – | 379 |
Uveitis | TUBCA | − | IRE1α | IRE1/NOD2 pathway and NLRP3 inflammasomes | Downregulation of ER stress via inflammation inhibition | – | 382 |
Uveitis | Galectin-3 | − | UPR pathway | The whole ER stress pathway | Downregulation of ER stress in BS | – | 390 |
Uveitis | Mesalazine | − | UPR pathway | The whole ER stress pathway | Alleviation of inflammation via ER stress reduction in BS | – | 389 |
Uveal melanoma (UM) | 4-PBA | − | UPR pathway | The whole ER stress pathway | Effectively inhibit ER stress in BRAF-mutated melanoma | Heart, lung, and kidney injury | 408 |
UM | Pemetrexed | + | CHOP | CHOP/ NOXA/ Mcl-1 pathway | Facilitate ER stress-induced intrinsic apoptosis | – | 410 |
UM | Navitoclax | − | PERK | PERK pathway | Blocking ER stress-induced drug resistance to facilitate tumor apoptosis | – | 407 |
UM | Combining targeted ER stress therapy with immunotherapy | − | UPR pathway | The whole ER stress pathway | Inhibition of ER stress, which facilitates immunotherapy effects | – | 412 |
UM | Nanosystems | − | ER | The whole ER stress pathway | Directly inhibit ER stress to strengthen antitumor drugs effects | – | 412 |
UM | SCD1 inhibitor | − | UPR pathway | The whole ER stress pathway andβ-catenin signaling | Production of antitumor CD8+ T cell by inhibiting ER stress | In human colon cancer | 412 |
Corneal dystrophy | 4-PBA | − | UPR pathway | The whole ER stress pathway | Reinforce ER stress and degrade TGFBIp by relieving ER stress | Heart, lung, and kidney injury | 427 |
Corneal dystrophy | Melatonin | − | The UPR pathway | IRE1α/XBP1 pathway | Inhibition of ER stress to save GCD2 corneal fibroblasts | – | 431 |
Corneal dystrophy | Mitochondrial ROS quencher MitoQ | − | Bip and GADD153 | The whole ER stress pathway | Restore mitochondria function by inhibiting Bip and GADD153 | – | 416 |
Corneal dystrophy | Glafenine | − | Mutant SLC4A11 | The whole ER stress pathway | Facilitate SLC4A11 folding, which inhibit ER stress-induced cell loss | – | 435 |
Corneal dystrophy | Mesenchymal stem cell-derived extracellular vesicles | − | The UPR molecules | The whole ER stress pathway | Contain miRNA-targeted ER stress while facilitating cell survival in cornea | – | 436 |
Myopia | Salidroside | − | HIF-1α | HIF-1α/eIF2α | Inhibition of hypoxia-induced ER stress to prevent sclera remodeling | – | 463,464 |
Myopia | Formononetin | − | HIF-1α | HIF-1α/eIF2α | Inhibition of hypoxia-induced ER stress to prevent sclera remodeling | – | 463,464 |
Myopia | 4-PBA | − | The UPR pathway | The whole ER stress pathway | Normalize the vitreous chamber depth and retinal thickness via inhibition of ER stress | Heart, lung, and kidney injury | 459 |
Myopia | TUDCA | − | The UPR pathway | The whole ER stress pathway | Normalize the vitreous chamber depth and retinal thickness via inhibition of ER stress | – | 459 |
Myopia | CRIPR/Cas9 | − | PERK and ATF6 | PERK and ATF6 pathway | Normalize the vitreous chamber depth and retinal thickness via inhibition of ER stress | – | 458 |